Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in Arcutis Biotherapeutics stock on May 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/2/2026.
• Purchased $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 5/29/2026.
• Sold $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Independent Bank (NASDAQ:INDB) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Boston Scientific (NYSE:BSX) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Perella Weinberg Partners (NASDAQ:PWP) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Cooper Companies (NASDAQ:COO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Ligand Pharmaceuticals (NASDAQ:LGND) on 5/29/2026.
• Sold $15,001 – $50,000 in shares of Workday (NASDAQ:WDAY) on 5/29/2026.

Arcutis Biotherapeutics Stock Up 1.9%

NASDAQ ARQT traded up $0.44 during trading on Wednesday, reaching $23.23. 1,411,384 shares of the company’s stock traded hands, compared to its average volume of 1,507,163. Arcutis Biotherapeutics, Inc. has a 12-month low of $12.72 and a 12-month high of $31.77. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.68 and a quick ratio of 2.46. The firm has a market cap of $2.91 billion, a price-to-earnings ratio of -774.08 and a beta of 1.51. The company’s 50 day simple moving average is $22.48 and its two-hundred day simple moving average is $25.37.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.07). The business had revenue of $105.40 million for the quarter, compared to the consensus estimate of $103.68 million. Arcutis Biotherapeutics had a negative net margin of 0.57% and a negative return on equity of 1.41%. As a group, sell-side analysts forecast that Arcutis Biotherapeutics, Inc. will post 0.15 EPS for the current fiscal year.

Insider Transactions at Arcutis Biotherapeutics

In related news, Director Howard G. Welgus sold 7,144 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $22.99, for a total value of $164,240.56. Following the sale, the director owned 32,600 shares in the company, valued at $749,474. This represents a 17.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Todd Watanabe sold 3,172 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $23.61, for a total transaction of $74,890.92. Following the transaction, the insider owned 720,755 shares of the company’s stock, valued at $17,017,025.55. This represents a 0.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 31,254 shares of company stock worth $732,019. 9.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Suvretta Capital Management LLC increased its position in shares of Arcutis Biotherapeutics by 14.2% in the 4th quarter. Suvretta Capital Management LLC now owns 11,964,000 shares of the company’s stock valued at $347,435,000 after acquiring an additional 1,486,000 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Arcutis Biotherapeutics by 1,228.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,166,348 shares of the company’s stock worth $33,872,000 after acquiring an additional 1,078,546 shares during the period. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Arcutis Biotherapeutics during the 4th quarter valued at about $26,136,000. State Street Corp grew its stake in Arcutis Biotherapeutics by 18.2% during the 4th quarter. State Street Corp now owns 5,488,301 shares of the company’s stock valued at $159,380,000 after purchasing an additional 846,986 shares during the last quarter. Finally, Voloridge Investment Management LLC acquired a new position in shares of Arcutis Biotherapeutics in the third quarter valued at about $15,711,000.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Mizuho cut their target price on Arcutis Biotherapeutics from $37.00 to $35.00 and set an “outperform” rating on the stock in a research note on Monday, March 2nd. Wall Street Zen downgraded shares of Arcutis Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. TD Cowen boosted their price objective on shares of Arcutis Biotherapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research note on Friday, March 27th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 price target on shares of Arcutis Biotherapeutics in a report on Thursday, May 7th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $34.00.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.